PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
2.79
0.00 (0.00%)
At close: 4:00PM EST

2.79 0.00 (0.00%)
After hours: 5:37PM EST

Stock chart is not supported by your current browser
Previous Close2.79
Open2.77
Bid2.55 x 500
Ask2.92 x 1000
Day's Range2.74 - 2.79
52 Week Range1.96 - 3.55
Volume1,116,971
Avg. Volume1,587,113
Market Cap430.606M
Beta0.09
PE Ratio (TTM)5.67
EPS (TTM)0.49
Earnings DateFeb 21, 2018 - Feb 28, 2018
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-06-02
1y Target Est3.50
Trade prices are not sourced from all markets
  • Capital Cube28 days ago

    ETFs with exposure to PDL BioPharma, Inc. : December 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PDL BioPharma, Inc. Here are 5 ETFs with the largest exposure to PDLI-US. Comparing the performance and risk of PDL BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
    Zackslast month

    PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%

    PDL BioPharma, Inc, (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

  • Capital Cubelast month

    ETFs with exposure to PDL BioPharma, Inc. : December 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PDL BioPharma, Inc. Here are 5 ETFs with the largest exposure to PDLI-US. Comparing the performance and risk of PDL BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 12, 2017
    Capital Cubelast month

    PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 12, 2017

    Categories: Yahoo FinanceGet free summary analysis PDL BioPharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of PDL BioPharma, Inc. – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, LLY-US ... Read more (Read more...)

  • PR Newswire2 months ago

    Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older

    DUBLIN , Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced ...

  • AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
    Zacks2 months ago

    AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

    AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

  • Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss
    Zacks2 months ago

    Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

    Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth

    NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna ...

  • PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
    PR Newswire2 months ago

    PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process

    INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares. PDL is confident its proposal represents fair value for the Company and offers certain and compelling value for Neos shareholders.

  • Why Neos Therapeutics Inc Rose 13.7% In October
    Motley Fool2 months ago

    Why Neos Therapeutics Inc Rose 13.7% In October

    The game of cat and mouse continues.

  • PDL BioPharma to Present at Two Upcoming Investor Conferences
    PR Newswire2 months ago

    PDL BioPharma to Present at Two Upcoming Investor Conferences

    INCLINE VILLAGE, Nev. , Nov. 7, 2017 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two ...

  • PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y
    Zacks3 months ago

    PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

    PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PDLI earnings conference call or presentation 2-Nov-17 8:30pm GMT

    Q3 2017 PDL BioPharma Inc Earnings Call

  • Associated Press3 months ago

    PDL BioPharma posts 3Q profit

    The Incline Village, Nevada-based company said it had profit of 14 cents per share. Earnings, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...

  • ACCESSWIRE3 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 2, 2017 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern ...

  • Reuters3 months ago

    Neos Therapeutics to consider other offers after PDL snub -sources

    U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter. Neos, a developer of attention deficit disorder treatments, rejected, as inadequate, a nearly $300 million all-cash bid from PDL that was more than a 40 percent premium to its market value. PDL could clinch a deal if it were to offer a higher price, the sources added, cautioning that there was no certainty of any transaction.

  • PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
    PR Newswire3 months ago

    PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal

    INCLINE VILLAGE, Nev. , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, ...

  • MarketWatch3 months ago

    Neos Therapeutics' stock falls after rejecting PDL BioPharma's buyout bid

    Shares of Neos Therapeutics Inc. sank 3.5% in premarket trade Monday, after the company said it rejected PDL BioPharma Inc.'s unsolicited buyout bid. The drug maker said PDL's proposal to buy Neos for ...

  • PR Newswire3 months ago

    Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma

    DALLAS and FORT WORTH, Texas, Oct. 30, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Neos noted that PDL's October proposal is identical in all material respects to proposals received in June, July and September from PDL, which were also reviewed and unanimously rejected by the Neos Board. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Neos Board affirmed its previous determinations that PDL's proposal undervalues Neos, does not reflect Neos' strategic value and future prospects for continued growth and value creation, and is not in the best interests of the Company or Neos shareholders.

  • PDL BioPharma Announces Settlement Agreement with Valeant
    PR Newswire3 months ago

    PDL BioPharma Announces Settlement Agreement with Valeant

    INCLINE VILLAGE, Nevada, Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) today announced that on October 27, 2017, PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. and its indirect subsidiary Valeant Pharmaceuticals Luxembourg S.à r.l.

  • Capital Cube3 months ago

    PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : October 27, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives PDL BioPharma, Inc. a score of 53. Our analysis is based on comparing PDL BioPharma, Inc. with the following peers – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company, Enzon Pharmaceuticals, Inc. and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, ... Read more (Read more...)

  • Why Neos Therapeutics Inc (NEOS) Shares Climbed 37% Today
    SmarterAnalyst3 months ago

    Why Neos Therapeutics Inc (NEOS) Shares Climbed 37% Today

    Neos Therapeutics Inc (NASDAQ:NEOS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 37% upturn. The reason? PDL BioPharma (NASDAQ:PDLI) made a hostile bid to acquire Neos for $10.25 share in cash (40% upside from yesterday's close). PDL first formally proposed to acquire Neos on June 23, 2017, but Neos' board rejected the offer.

  • TheStreet.com3 months ago

    Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma

    Pharmaceutical company Neos received an offer for $10.25 per share, which would value the deal around $288 million. It's the third time PDL has tried to make a deal.

  • MarketWatch3 months ago

    Neos Therapeutics' stock rockets after buyout bid, says it will respond in 'due course'

    Shares of Neos Therapeutics Inc. rocketed 42% in morning trade Thursday, after the pharmaceutical company confirmed the receipt of an unsolicited buyout bid by PDL BioPharma Inc. for $10.25 a share, and ...

  • PR Newswire3 months ago

    Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharma

    DALLAS and FORT WORTH, Texas, Oct. 26, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the Neos Board of Directors will carefully review and consider the PDL proposal to determine the course of action that it believes is in the best interest of the Company and Neos shareholders.